PCM
RNAM

Pinz Capital Management’s Avidity Biosciences RNAM Stock Holding History

Pinz Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50,000
Closed -$1.41M – 170
2020
Q2 		$1.41M Buy
+50,000
New +$1.44M 0.65% 76

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pinz Capital Management's RNAM Position: Q3 2020 in Review

Pinz Capital Management sold out of Avidity Biosciences (RNAM) in Q3 2020, closing a stake of 50,000 shares — an estimated $1.41M sold.

Pinz Capital Management first reported a position in RNAM in Q2 2020 and held it in 1 quarter. The position peaked at $1.41M in Q2 2020. 67 funds tracked by Wall St. Rank hold RNAM as of Q3 2020.

  • Pinz Capital Management reported no remaining Avidity Biosciences position as of Q3 2020 after selling out during the quarter.
  • Pinz Capital Management sold 50,000 Avidity Biosciences shares in Q3 2020, an estimated $1.41M.
  • Pinz Capital Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 1 quarter.
  • Pinz Capital Management's Avidity Biosciences position peaked at $1.41M in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2020.

Based on Pinz Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.